No title
BACKGROUND: The tau-PET radiotracer [18F]flortaucipir enables in vivo detection of tau pathology in Alzheimer's Disease (AD) and has recently been FDA- and EMA-approved for clinical use. To support its implementation, we assessed tau-PET's positive predictive value (PPV) and negative predictive value (NPV) for clinico-pathological AD while accounting for age, amyloid-status, and pre-PET diagnostic
